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Resistance to macrolides in Streptococcus pneumoniae is usually mediated by methylation of 23S ribo-
somal RNA, encoded by the erm(B) methylation gene, or by efflux mediated by the mef(A) gene. Changes in
the L4 and L22 ribosomal proteins have also been associated with macrolide resistance and reduced
telithromycin activity. This study generated in vitro mutants from three parent strains of S. pneumoniae:
02J1175 [mef(A) +], 02J1095 [erm(B) +] and NCTC 13593 (macrolide susceptible). The erm(B) and the erm(B)
upstream region, the mef(A) genes and the mef(A) upstream and downstream regions, the 23S rRNA genes
encoding domains II and V and the L4 and L22 genes of the telithromycin-resistant strains were all amplified
by PCR and all, except the mef(A) upstream and downstream regions, were sequenced. No changes were
present in any of the genes of the mef(A) + mutants. No changes were found in the erm(B) genes, the 23S
rRNA genes or the L4 protein genes of the erm(B) + mutants. However, a Lys-94 to Gln-94 amino acid
mutation did occur in a mutant derived from erm(B) + with a telithromycin MIC of >32 mg/L. A 210 base pair
deletion in the erm(B) upstream region was also present in this strain. We believe this is the first incidence of
a Lys-94 to Gln-94 change in L22 associated with telithromycin resistance and also the first time that such a
large deletion in the erm(B) upstream region has been identified in S. pneumoniae.
Keywords: telithromycin, Streptococcus pneumoniae, resistance
Introduction
Macrolide resistance is currently an increasing problem in Strepto-
coccus pneumoniae throughout the world. The countries with the
highest levels of erythromycin A resistance between 1999 and 2001
worldwide were South Korea (86.2%), Japan (77.9%) and Hong
Kong (72.9%). In Europe, France (58%) and Italy (44.6%) have the
highest levels of erythromycin A resistance. The UK and USA had
resistance levels of 13.2% and 30%, respectively.1
The two most regularly identified mechanisms of macrolide resist-
ance in S. pneumoniae are target modification and efflux. Target
modification causes resistance not only to macrolides but also to
lincosamides and streptogramin B antibiotics and is associated with
high-level macrolide resistance.2 erm genes cause methylation of the
binding site of the MLSB antibiotics within the peptidyl transferase
centre of the 23S rRNA. In S. pneumoniae, the erm(B) gene mediates
methylation, although recently an erm(A) gene has also been asso-
ciated with macrolide-resistant S. pneumoniae.3,4 Methylation can
occur as monomethylation or dimethylation. It has recently been
shown that variations in mono- or dimethylation lead to different
resistance phenotypes. Erm(B) and Erm(A)(TR) are both A2058
dimethyltransferases and expression of resistance due to erm methyl-
ation can be inducible or constitutive.5
The inducible expression of MLSB resistance is putatively con-
trolled at a post-transcriptional level by a regulatory region upstream
from the erm gene.6 The exact mechanism or mechanisms of cons-
titutive resistance have not been fully elucidated in S. pneumoniae.
Constitutive expression of MLSB resistance in various bacteria has
been associated with deletions or mutations in the regulatory region
upstream from the erm gene.7 Two S. pneumoniae clinical isolates
with deletions in the leader peptides of their erm(B) genes have been
isolated, one each from Mexico and Canada, and both were ketolide-
resistant. In these strains, however, there were also other mutations;
both had three amino acid mutations in the Erm protein itself, and the
Mexican strain also had mutations in the L4 riboprotein.8
The mef(A) genetic element was first described in 2000 as a chromo-
somal element designated Tn1207.1, 7244 base pairs in size.9 In
2001, Gay & Stephens described a 5.4 or 5.5 kb genetic element
containing a mef(E) gene called MEGA.10 In MEGA, the open reading
frame (ORF) sequence 3′ of the mef(E) gene was designated mel. The
mel ORF is also a homologue of msrA in staphylococci, which
encodes an ATP-binding cassette to provide the energy for efflux.
The mef(E) and mel are co-transcribed, which suggests that both are
required for efflux.
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Macrolide resistance in clinical isolates and laboratory-derived
strains of S. pneumoniae have been linked to alterations of specific
nucleotides in the 23S rRNA of the ribosomal subunit. Mutations at
adenine 2058 are the most frequently identified ribosomal mutations
associated with macrolide resistance in 23S rRNA.11 Specifically in
S. pneumoniae, mutations have been located at nucleotides 2058,
2059, 2062 and 2611.12–15 These ribosomal mutations were identified
in clinical isolates, which did not contain the erm(B) or mef(A)
genes. In addition to these mutation sites, a mutation in the hairpin 35
region of the domain II of the 23S rRNA has been associated with
macrolide and ketolide resistance in a laboratory-derived mutant of
S. pneumoniae.16 This laboratory-derived S. pneumoniae strain was
found to have a deletion of one adenine in the series of four located at
positions 749–752 in the hairpin 35 of domain II.16
The ribosome consists not only of rRNA but also riboproteins,
which interact with the rRNA to form the ribosomal subunits. Two
such riboproteins are L4 and L22. Recently, mutations in both of
these riboproteins have been associated with macrolide resistance
in S. pneumoniae. Positively charged residues of both L4 and L22
interact with the negatively charged phosphate groups of the RNA
forming nucleic acid–protein complexes.17,18 Erythromycin resistance
mutation studies of these riboproteins implied that they also have
interactions with the central loop of domain V of the rRNA. Gregory
& Dahlberg also showed that these proteins have multiple contacts
with rRNA in domains II, III and V of the rRNA.19
Mutations in the L4 riboprotein and L22, to a lesser extent, have
been associated with macrolide and, on occasion, telithromycin
resistance, either alone or in combination with 23S rRNA mutations
or the presence of an erm(B) gene.4,14–16 From the studies carried out
to date, it appears that the L4 amino acid region from 67 to 72 is the
hotspot for mutations conferring macrolide resistance.4,14–16
Mutations in L22 associated with macrolide resistance have been
mainly described in laboratory-derived strains of S. pneumoniae. In
fact, only two types of L22 mutation have been identified in clinical
isolates. They are a Gly-95 to Asp-95 amino acid change, and a six
amino acid insertion (RTAHIT) at amino acid 109.12,20 Three strains
selected in vitro on telithromycin were identified recently with two
types of L22 mutation; one strain had a Gln-95 to Asp-95 mutation
and the other an Ala-97 to Asp-97 change. These strains were not
telithromycin-resistant but the mutation did cause the telithromycin
MIC to increase 32-fold for the Gln-95 to Asp-95 mutant and 8- or 16-
fold for the Ala-97 to Asp-97 mutants.21
The generation of telithromycin-resistant S. pneumoniae mutants
to date has mainly used macrolide-susceptible S. pneumoniae to try to
develop telithromycin-resistant mutants. Therefore, we decided
to investigate telithromycin resistance development from S. pneu-
moniae, which were already macrolide resistant. The aim of this
study was to investigate the development of telithromycin resistance
in S. pneumoniae by generating telithromycin-resistant mutants in
vitro, from strains of varying MLSB resistance profiles. Once the
mutants were generated, the mechanisms by which these strains
became telithromycin-resistant and finally the influence of erythro-
mycin and clarithromycin on the development of telithromycin
resistance were studied.
Materials and methods
Bacterial strains
The three S. pneumoniae strains used as the parents for the step-wise
selection of telithromycin-resistant mutants were 02J1175 [mef(A)+],
02J1095 [erm(B) +] and NCTC 13593, which is a macrolide-susceptible
strain and does not contain either gene.
Mutation studies
Each of the three parent strains were inoculated into Todd Hewitt
broth (Oxoid) and incubated in 5% CO2 overnight. Varying dilutions,
from neat to 10–6, of the cultures were spread on Columbia agar
(Sigma–Aldrich) plates supplemented with 5% defibrinated horse
blood containing telithromycin at concentrations equal to or 2 × MIC
for the strain. Plates with each concentration of telithromycin were
inoculated in triplicate and a control with no antibiotic was also
included. All plates were incubated in 5% CO2 for 48 h. The resulting
mutants were purified by subculturing twice on plates with the selectant
telithromycin concentration. The MICs of telithromycin against the
mutants were tested at this point according to the BSAC guidelines.22
Successive generations of mutants were derived in the same way as
the first generation. This process was repeated until high-level
telithromycin resistance occurred or the MICs for successive gen-
erations remained constant. Serially subculturing the mutants on
antibiotic-free medium for 10 generations and then retesting their
telithromycin MICs was used to determine the stability of a represent-
ative of each generation.
MIC determination
MICs were determined on Columbia agar supplemented with 5% defibrin-
ated horse blood and doubling dilutions of antibiotic according to the
BSAC guidelines.22 All plates were incubated in 5% CO2 for 16–18 h.
The antibiotics were stored and prepared according to the manufacturer’s
guidelines. Telithromycin was obtained from Aventis Pharma Ltd.
PCR conditions
S. pneumoniae strains were emulsified in 200 µL of Milli-Q water and
boiled for 10 min in order to extract the total DNA. The supernatant was
used as the DNA template in the PCR experiments. The PCR conditions
and primers for the detection of erm(B) and mef(A) genes are described in
Table 1 and are based on those previously devised by Sutcliffe et al. and
Tait-Kamradt et al.23,24 The mef(A) gene reverse primer was designed
using the primer design website Primer 3 at http://www-genome.wi.
mit.edu/cgi-bin/primer/primer3_www.cgi in order to amplify the entire
mef(A) gene. The three parents 02J1095, 02J1175 and NCTC 13593 and
the selected generation representative mutants, shown in Table 2, were
investigated for the presence of erm(B) or mef(A) genes.
The mel gene and mef(A) upstream region of the bacterial strain
02J1175 and the mutants M I 2, M II 15, M III 3 and M IV were amplified
by PCR. The primers used to amplify the mel genes and upstream regions
were previously described by Gay & Stephens and Sutcliffe et al., except
for the mef(A) upstream forward primer (Table 1).10,23 This was designed
with the primer design website Primer 3 at http://www-genome.wi.mit.
edu/cgi-bin/primer/primer3_www.cgi. The mef(A) upstream reverse
primer was the same as the reverse primer used to amplify the mef(A)
gene and the mel forward primer was the forward primer used to amplify
the mef(A) gene. Their respective positions in the MEGA insertion
element are mef(A) upstream reverse primer, nucleotides 1506–1525 and
the mel forward primer, nucleotides 1181–1201.
The erm(B) upstream regions of the parent strain 02J1095 and
mutants J I 1, J II 1, J II 4, J II 5, J II 6, J II 7, J II 8 and J II 9 were investi-
gated by amplification by PCR. The forward primer was designed using
the primer design website Primer 3 at http://www-genome.wi.mit.edu/
cgi-bin/primer/primer3_www.cgi and the reverse primer was the same as
the reverse primer used to amplify the erm(B) gene described in Table 1.
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The PCR mixture was the same as that of the erm(B) gene PCR except the
MgCl2 concentration was 3 mM. The cycle parameters were the same as
those of the erm(B) PCR.
In order to detect mutations in the peptidyl transferase region of the
23S rRNA, all four contigs of the domain V section were amplified using
the four downstream primers and PCR conditions as published by Tait-
Kamradt et al. and shown in Table 1.15 Problems were encountered in
obtaining the sequence data for the nucleotide section from 2350 to 2650
of the DS 18 and DS 23 genes, as they were both 2000 nucleotides in size.
As a result, primers were designed to amplify this inner portion of each of
the genes. The PCR products of the downstream primers were purified
and this product was then used as the DNA template for the inner PCR
experiments. The primers are shown in Table 1. The inner primer PCR
consisted of 94°C for 3 min, 35 cycles of 94°C for 1 min, 54°C for 1 min
and 72°C for 1 min and a final step of 72°C for 10 min. The domain II
portion of the 23S rRNA was amplified by using the domain II primers
(Table 1) and conditions of Tait-Kamradt et al.15 The L4 and L22 genes
were also amplified as previously published using the primers shown in
Table 1.15
The PCR products were purified by the gel extraction method or
directly using the Qiagen PCR product purification kit.
Sequencing
Sequencing of purified DNA was determined by the chain termination
method.25 The PCR primers were also used as sequencing primers. Indi-
vidual PCR fragments were set up in the Ready Reaction Format for
fluorescence based on dideoxy cycle sequencing (PE Applied Systems,
Warrington,  UK).
Induction experiments
Disc diffusion: The strains 02J1095, J I 1, J II 1, J II 8 and the control strain
NCTC 13593, described in Table 2, were each inoculated into 4.5 mL of
sterile distilled water and adjusted to a turbidity equivalent to that of a 0.5
McFarland standard. Using a sterile swab, each strain was spread onto
separate Columbia blood agar plates. Discs containing 15 µg of each of
the following agents—erythromycin, clarithromycin and telithromycin—
were placed onto the plate approximately 2 cm apart. Each strain was
tested in duplicate.
Induction assays: In order to investigate inducibility further, two induc-
tion assays were carried out.
1 The parent 02J1095 [erm(B) +] was subcultured on erythromycin,
and the resulting mutants were tested for induction of telithromycin
resistance. 02J1095 was inoculated into sterile saline and adjusted
to a turbidity equivalent to that of a 0.5 McFarland standard. One
hundred microlitres was spread on Columbia blood agar plates con-
taining 4, 8, 16, 32, 64 and 128 mg/L each of erythromycin and a
control plate with no antibiotic and incubated in 5% CO2 overnight.
Colonies were randomly chosen from each plate and subcultured on
plates containing the appropriate erythromycin concentration and
incubated overnight in 5% CO2. The MIC of telithromycin against
these mutants was investigated as previously described. S. pneumoniae
NCTC 13593, S. aureus NCTC 6571 and E. coli NCTC 10418 were
all used as controls in the MIC tests.
2 The MICs of telithromycin in the presence of erythromycin (4, 8,
16, 32, 64 and 128 mg/L) for strains 02J1095 and all the mutants
were determined as previously described. Control strains consisted
of the S. pneumoniae NCTC 13593 and S. aureus NCTC 6571.
Table 1. PCR primers
Primer name Sequence 5′ to 3′
erm(B) forward GAA AA(AG) GTA CTC AAC CAA ATA
erm(B) reverse AGT AA(CT) GGT ACT TAA ATT GTT TAC
mef(A) forward AGT ATC ATT AAT CAC TAG TGC
mef(A) reverse TTC TTC TGG TAC TAA AAG TGG
erm(B) upstream forward GAA GCA AAC TTA AGA GTG TGT TGA
erm(B) upstream reverse AGT AA(CT) GGT ACT TAA ATT GTT TAC
mef(A) upstream forward GAG CAT TCA TTA GTT ACG GTG AGG
mef(A) upstream reverse TTC TTC TGG TAC TAA AAG TGG
mel forward AGT ATC ATT AAT CAC TAG TGC
mel reverse CTT CAC GGT CTA AAT GGC TCG
23S 3′ forward CGG CGG CCG TAA CTA TAA CG
23S 3′ reverse
DS 18 GCC AGC TGA GCT ACA CCG CC
DS 23 TAC ACA CTC ACA TAT CTC TG
DS 30 TTT TAC CAC TAA ACT ACA CC
DS 91 TAC CAA CTG AGC TAT GGC GG
Inner primers
forward GTT CCC TCA GAA TGG TTG GA
reverse CAT AGC TAC CCA GCG ATG C
Domain II
forward GGT TAA GTT AAT AAG GGC GC
reverse TTT CGA CTA CGG ATC TTA GC
L4 forward AAA TCA GCA GTT AAA GCT GG
L4 reverse GAG CTT TCA GTG ATG ACA GG
L22 forward GCA GAC GAC AAG AAA ACA CG
L22 reverse ATT GGA TGT ACT TTT TGA CC
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Results
Mutation studies
Telithromycin-resistant mutants were created from the macrolide-
resistant strains 02J1095 [erm(B) +] and 02J1175 [mef(A) +]. Selec-
tion of the macrolide-susceptible NCTC 13593 strain on telithro-
mycin failed to produce telithromycin-resistant mutants (Table 2).
The MIC of 02J1095 and its mutants increased from 0.06 mg/L
for the parent 02J1095 to >32 mg/L over two generations (Table 2).
The first generation increase from 0.06 to 1 mg/L was a 16-fold
increase; from first to second generation, the increase was greater
than 32-fold. These increases were stable, such that when the mutants
were serially subcultured 10 times, without the selective pressure of
telithromycin, they still maintained the same telithromycin MIC.
The telithromycin MIC of the parent 02J1175 was 0.5 mg/L. The
first generation mutants had telithromycin MICs between 1 and 4 mg/L
(Table 2). The representative mutant, M I 2, selected to create the
second generation had an MIC of 2 mg/L. This gave rise to a second
generation with MICs between 2 and 4 mg/L. The third and fourth
generations both had telithromycin MICs of 8 mg/L and further
mutants with higher telithromycin MICs could not be obtained
from them. The telithromycin MIC of the most resistant strain, fourth
generation 02J1175 mutant, reverted from 8 to 1 mg/L after 10
passages in antibiotic-free medium. The MICs of M III 3 and M II 15
also decreased but only by one doubling dilution. The MIC of M I 2
decreased by two doubling dilutions. For the third generation strain,
this means that its telithromycin resistance remained stable with an
MIC of 4 mg/L. When the reverent strain of the fourth generation
02J1175 mutant was mutated on agar plates containing either 1 or
2 mg/L, all the resulting mutants returned to an MIC of 8 mg/L,
the same as the fourth generation mutant. Therefore, in order for
S. pneumoniae strains with a mef(A) gene to maintain their telithro-
mycin MIC, selective pressure must be maintained. This has pre-
viously been noted by Davies et al.,26 when the telithromycin and
macrolide MICs reverted back to baseline MICs (or close to) after 10
passages on antibiotic-free media. This is not true for those contain-
ing the erm(B) gene. Once resistance or an elevated telithromycin
MIC has been achieved, it is stable with or without the selective
pressure.
The NCTC 13593 strain, which was macrolide-susceptible, had a
telithromycin MIC of 0.016 mg/L. This increased sequentially to
0.032, 0.12, 0.5 and 0.5 mg/L for the four mutant generations,
respectively (Table 2). The final generation mutants were telithro-
mycin-susceptible.
PCR and sequencing of erm(B) and mef(A)
 A representative of each mutant generation was chosen for further
molecular analysis. The 02J1095 parent and all mutants tested con-
tained the erm(B) gene, determined by PCR amplification. In order to
investigate the mechanism of telithromycin resistance, the erm(B)
gene from each representative mutant was amplified by PCR and
sequenced. The same procedure was carried out on 02J1175 and its
representative mutants with the mef(A) gene (Table 2). No mutations
were found in either the erm(B) or mef(A) genes. No erm(B) or
mef(A) genes were present in the NCTC 13593 parent or its mutants.
The strains only contained an erm(B) gene or a mef(A) gene, and no
strains were positive for both genes.
The erm(B) upstream region of 02J1095 and the selected mutants,
described in Table 2, was amplified by PCR in order to investigate the
nucleotide region from the promoter to the erm(B) gene. Deletions in
this region have been associated with a change from inducible to
constitutive erythromycin A resistance.7,27 The corresponding bands
of approximately 1000 base pairs of the erm(B) upstream region PCR
products of 02J1095 and the selected mutants (Table 2) were visual-
ized on the agarose gels. The J II 8 band however was just above the
750 bp band of the 1 kb ladder as shown in Figure 1.
The sequencing results showed some anomalies not only in J II 8
but also in each of the other strains, in comparison to the erm(B)
upstream sequence of the Tn1545 of S. pneumoniae in the NCBI
website. The gene comparator was accession number X52632. The
nucleotide changes are listed in Table 3 and their positions relative to
the putative promoter (–35 and –10 sequences), the ribosome binding
Table 2. Selected representative mutants
Telithromycin MICs are given in parentheses.
Parent
NCTC 13593 
(0.016 mg/L)
02J1095 erm(B) + 
(0.06 mg/L)
02J1175 mef(A) + 
(0.5 mg/L)
Generation 1 NCTC 1 (0.032 mg/L) J I 1 (1 mg/L) M I 2 (2 mg/L) 
Generation 2 NCTC 2 (0.12 mg/L) J II 1 (4 mg/L) M II 15 (4 mg/L)
J II 4 (16 mg/L)
J II 5, 6 (32 mg/L)
J II 7 to 9 (>32 mg/L)
Generation 3 NCTC 3 (0.5 mg/L) M III 3 (8 mg/L)
Generation 4 NCTC 4 (0.5 mg/L) M IV (8 mg/L)
Figure 1. erm(B) promoter PCR gel.
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sites (RBS) and control peptide are indicated in Figure 2. The G-292,
T-297 and G-319 are all present in the erm(B) carrying plasmid pAM
77 of Streptococcus sanguis and the T318A mutation has previously
been identified in an oral streptococci.7,27 The C297T, A292G and the
T318A, A319G mutations have been located in clinical isolates of
S. pneumoniae, which had inducible expression of the erm(B)
gene.7,27 The mutations that were present only in J II 1, J II 4, J II 7
and J II 9 have not been previously identified. Similar deletions of
large fragments of nucleotides upstream from the erm(B) gene have
been located in Streptococcus agalactiae (HM1081) and S. pneumo-
niae (HM36), which had constitutive erm(B) expression.7,27 The
plasmid pAMβ1 of Enterococcus faecalis also contained the same
deletion as these strains.7,27 However, in these strains this deletion
removed the first RBS and the control peptide but J II 8 had a deletion
of the second RBS and the control peptide.
The mef(A) upstream region PCR products and the mel genes of
the strains were amplified and the corresponding PCR bands at 614
and 1680 bp, respectively were visualized on the agarose gel. There
were no changes in the sizes of the mef(A) upstream region, contain-
ing the promoter, or the downstream mel region in any of the mutants.
The sequencing results of the entire mef(A) gene indicated no
changes in either the parent 02J1175 or the representative mutants.
Induction experiment results
On both plates, with 02J1095 and J I 1 (Figure 3), the zone of inhibition
around telithromycin had two straight edges, one each from erythro-
mycin and clarithromycin. The D-shaped zone indicates that the
antimicrobial agent to the left of the D induces resistance. From
these photographs (Figure 3), it can be seen that erythromycin and
clarithromycin both induce telithromycin resistance. The growth of
J II 1 to J II 9 was either up to the discs or within 1 mm of the discs
and so were recorded as resistant to the three antimicrobial agents
and, as such, had constitutive expression of the erm(B) gene.
Induction assays
The MICs of the mutant strains derived from growth of 02J1095 on
erythromycin are shown in Table 4. The telithromycin MICs of the
strains tested in the presence of erythromycin are shown in Table 5.
The first set of MICs indicated that when 02J1095 was sub-
cultured in the presence of erythromycin, the telithromycin MIC of
all the mutant strains increased to 1 mg/L, regardless of the concen-
tration of erythromycin that it was exposed to.
With regard to the second MIC test, the MICs of 02J1095 and all of
the first generation mutants did increase. The telithromycin MICs of
the already highly resistant second-generation strains increased or
decreased regardless of the concentration of erythromycin. The
telithromycin MIC of the parent 02J1095 increased from 0.06 to
1 mg/L or 2 mg/L and that of the first generation mutants increased
gradually from 0.25 to 32 mg/L and that of the second generation
mutants increased from 4 to >32 mg/L depending on the strain and the
concentration of erythromycin. Therefore, as indicated by the disc
diffusion test and the two induction tests, erythromycin does induce
telithromycin resistance. However, the level of induction varies
depending on the initial telithromycin MIC and does not increase
beyond a telithromycin MIC of 64 mg/L.
Ribosomal mutations
Mutations in the domains II and V of the 23S rRNA have previously
accounted for increases in MIC of both macrolides and telithro-
mycin.12,14,15,28–30 Therefore, it was plausible to speculate that
changes in either or both of these regions could be responsible for
the increase in telithromycin MIC. The region of 23S rRNA from
nucleotide 1 to 1011, representing domain II, of the two most resist-
ant strains J II 8 and M IV was amplified and sequenced. No heteroge-
neity in the nucleotide sequences of the hairpin 35 was observed.
Thus no changes were present in any of the four alleles of the 23S
rRNA.
All four genes of the domain V region of 23S rRNA were ampli-
fied and sequenced individually. Again the domain V sequences
were identical to those of the TIGR 4 strain sequences.31 This indi-
cates that no changes were present in the peptidyl transferase region
of the 23S rRNA
Table 3. Nucleotide mutations in the erm(B) upstream region
Mutant strains 
(telithromycin MIC mg/L)
Nucleotide changes in comparison
 to erm(B) of Tn1545
02J1095 (0.06) A292G, C297T, T318A, A319G
J I 1 (1) A292G, C297T, T318A, A319G
J II 1 (4) A292G, C297T, T318A, A319G, C324A
J II 4 (16) A292G, C297T, T318A, A319G, C307T
J II 5 (32) A292G, C297T, T318A, A319G
J II 6 (32) A292G, C297T, T318A, A319G
J II 7 (>32) A292G, C297T, T318A, A319G, G302A
J II 8 (>32) 210 bp deletion from 113 to 322
J II 9 (>32) A292G, C297T, T318A, A319G, T322G
Figure 2. Sequence alignment of erm(B) upstream region.
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The lack of mutation in the 23S rRNA suggested that changes
could be present in L4 and L22 ribosomal proteins associated with the
peptidyl transferase region. Changes in the L4 and L22 have been
implicated in decreased susceptibility of S. pneumoniae to telithro-
mycin and erythromycin.15,16,32 The L4 protein genes of 02J1095,
J II 8 [erm(B) +], 02J1175 and M IV [mef(A) +] were amplified and
sequenced. No changes, insertions or deletions occurred in either
resistant strain in comparison to the susceptible TIGR 4 strain or the
macrolide-resistant parent strains. Using primers described by Tait-
Kamradt et al., the genes encoding the L22 protein of 02J1095, J I 1,
J II 1, J II 4, J II 5, J II 6, J II 7, J II 8, J II 9, 02J1175 and M IV were
amplified and sequenced.15 Again, there were no changes present in
any of the strains tested except one strain, J II 8, in which a Lys-94 to
Gln-94 change was determined (Figure 4). This change was due to an
adenine to cytosine change. This is the first incidence of a Lys-94 to
Gln-94 change in L22 being associated with telithromycin resistance.
Discussion
The mutants generated from a strain with the erm(B) gene were
stable, unlike the mutants from a mef(A)-positive strain. However,
the mef(A) revertants only required the presence of telithromycin to
return immediately to the highest telithromycin MIC once more.
They did not return to the telithromycin MIC of 8 mg/L by stepwise
selection but merely in one step, which suggests a compensatory
mutation. Strain NCTC 13593 did not have either the erm(B) or
mef(A) genes present. The highest telithromycin MIC of any NCTC
13593 mutant was 0.5 mg/L, which is still clinically susceptible. It is
interesting to note that in the erythromycin A-resistant strains either
due to the erm(B) gene or mef(A) gene, telithromycin resistance
emerged after only two generations. To date telithromycin-resistant
mutants have usually been derived from macrolide-susceptible
parent strains, which could explain why the results of this study vary
from many of those previously published. However, Davies et al.
passaged S. pneumoniae strains, which were mef(A)-positive, erm(B)-
positive or macrolide-susceptible on a variety of antimicrobial
agents.26 The number of passages required for telithromycin resist-
ance to emerge varied. The macrolide-susceptible strain required 24
passages on telithromycin for a strain with a telithromycin MIC of
8 mg/L to emerge, whereas a strain with an erm(B) gene required only
three passages in telithromycin to result in a mutant with a telithro-
mycin MIC of 8 mg/L.
The results of the erm(B) and mef(A) gene sequencing indicated
that no changes in either gene were associated with telithromycin
resistance. Therefore, whereas these genes are required for the selec-
tion of telithromycin resistance, they themselves do not change to
facilitate telithromycin resistance.
Deletions in the erm gene attenuator region in Streptococcus pyo-
genes, S. pneumoniae and S. agalactiae have all been associated with
constitutive expression of their Erm methylases. In S. pyogenes, dele-
tions of 163 base pairs or six base pairs and a duplication of 101 base
pairs in the erm(TR) upstream region resulted in an increase in clinda-
mycin MIC from 1 to 128 mg/L when transformed into E. coli.33 The
S. pyogenes strains with mutated attenuators were mutants, which
had been selected on clindamycin, and the parent strain was inducibly
intermediate to erythromycin and fully susceptible to clindamycin.
Tait-Kamradt et al. described two S. pneumoniae clinical isolates
with truncated erm(B) leader peptides of 15 and 19 amino acids.8
Figure 3. Induction experiment results. (a) Parent strain 02J1095 with discs of
erythromycin, clarithromycin and telithromycin; (b) mutant J I 1 with discs of
erythromycin, clarithromycin and telithromycin.
Table 4. Telithromycin MICs of erythromycin 
generated mutants
E4, E8, E16, E32, E64 and E128 numbered 1 to 3 are
the mutants subcultured on erythromycin at 4, 8, 16, 32,
64 and 128 mg/L, respectively.
Strain Telithromycin MIC (mg/L)
02J1095 0.06
No antibiotic 0.06
E4 1–3 1
E8 1–3 1
E16 1–3 1
E32 1–3 1
E64 1–3 1
E128 1–3 1
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These two strains had telithromycin MICs of 1 and 256 mg/L,
respectively and both also had changes in the gene itself, leading to
three amino acid changes. The strain with the 256 mg/L telithromycin
MIC also contained L4 riboprotein amino acid mutations of glycine,
threonine and glycine at amino acids 69 to 71 to threonine, proline
and serine, respectively.
The results of the PCR experiments of the erm(B) upstream region
carried out with the parent 02J1095 and the mutants derived from
it showed that the J II 8 strain had a large deletion of 210 bp in this
section. This result is very similar to that found with the clindamycin-
resistant S. pyogenes. Therefore, it is possible that a mechanism of
resistance exists that alters the erm(B) attenuator of strains inducibly
resistant to erythromycin in order to confer resistance to other anti-
microbial agents within the same group, such as clindamycin and
telithromycin. The results of Tait-Kamradt et al. are similar to the
findings of this study in that the telithromycin-resistant strains both
had truncated regions upstream from the erm(B) gene.8 The other
mutants investigated in this study, which were also highly telithro-
mycin-resistant, did not however have such a deletion. Therefore,
whereas the mutation in the erm(B) attenuator may be at least partly
responsible for telithromycin resistance in J II 8, this is not the case
for the other five highly telithromycin-resistant strains.
The mutated nucleotides of the strains investigated at positions
292, 297 and 319 are the same nucleotides as those of plasmid pAM 77
from Streptococcus sanguis and the nucleotide change at position
318 was found previously in an oral streptococcus.7,27 These muta-
tions were in the parent 02J1095 and all the mutants, except J II 8, and
as such do not appear to be involved in the development of telithro-
mycin resistance. It is, however, interesting to note the nucleotide
changes at 318 and 319 are just at the end of the deletion in J II 8. Two
previously reported S. pneumoniae isolates with the same 318 and
319 mutations were both inducibly erythromycin-resistant but sus-
ceptible to the ketolide HMR 3004.27 The other single mutations in
J II 1, J II 4, J II 7 and J II 9 have not previously been associated with
changes in resistance patterns. But as each strain has a different
mutation, it is unlikely that these mutations individually lead to
telithromycin resistance.
The disc diffusion experiments indicated, from the D-shaped
zones of inhibition around the telithromycin disc, that erythromycin
and clarithromycin are both inducers of telithromycin resistance in
the strains 02J1095 and J I 1. This finding was verified by two further
induction studies with erythromycin at concentrations from 4 to
128 mg/L. There were variations in the increase in telithromycin MIC
but the increase in telithromycin MICs in all strains caused a change
from telithromycin-susceptible to non-susceptible or resistant. This
is the first report of erythromycin induction of telithromycin resistance
in S. pneumoniae.
The high-level telithromycin MICs for the mutants are not all
caused by the same mutation in the erm(B) attenuator. Although the
large deletion in J II 8 is such that it is probably part of the mechanism
used by this strain to overcome telithromycin, the sizes of the
upstream and downstream regions from the mef(A) genes suggest
that no large nucleotide deletions have occurred. The presence of the
mel genes in these strains confirms previous studies of the mef(A)
operon, which suggested the presence of the mel gene downstream
from the mef(A) gene. From this study, it can be seen that deletions
of large numbers of nucleotides from either the upstream or down-
stream nucleotide regions of the mef(A) gene are not responsible for
the increase in telithromycin MIC and resistance.
The main regions of interest to date for macrolide resistance in
S. pneumoniae in the 23S rRNA are the domains II and V. The area of
consequence in domain II is the hairpin 35. A deletion in one adenine
in the series of four located at positions 749 to 752 resulted in a
500-fold increase in the telithromycin MIC for a S. pneumoniae strain.
In this case, it became resistant to telithromycin (4 mg/L).16 Pre-
viously, a single point mutation (U754A) in a laboratory strain of
Table 5. Telithromycin MICs of erm(B) + mutants in the presence of increasing concentrations of erythromycin
TEL, telithromycin; ERY, erythromycin.
Strain
TEL MIC 
(no ERY)
TEL MIC 
(ERY 4 mg/L)
TEL MIC 
(ERY 8 mg/L)
TEL MIC 
(ERY 16 mg/L)
TEL MIC 
(ERY 32 mg/L)
TEL MIC 
(ERY 64 mg/L)
TEL MIC 
(ERY 128 mg/L)
02J1095 0.06 1 1 1 1 2 2
J I 1 1 8 4 8 8 16 16
J I 2 2 8 8 8 4 32 16
J I 3 0.25 4 4 4 4 8 16
J I 4 0.5 8 8 16 8 16 32
J I 5 0.5 4 4 4 4 8 8
J I 6 0.5 8 8 8 8 32 32
J I 7 2 8 8 8 8 32 32
J II 1 4 16 16 16 16 32 32
J II 2 32 64 64 32 64 64 64
J II 3 32 16 32 16 16 32 32
J II 4 16 4 4 4 4 4 8
J II 5 32 32 32 32 32 64 32
J II 6 32 32 32 32 32 32 32
J II 7 >32 32 32 32 32 32 32
J II 8 >32 64 32 64 32 32 64
J II 9 >32 32 32 32 32 64 32
 at M
aynooth U
niversity on Septem
ber 23, 2016
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
F. Walsh et al.
352
E. coli resulted in the cells being resistant to telithromycin.30 For
domain V there is less specificity with regard to one macrolide-
resistant region. Nucleotide changes have been located at 2058, 2059
and 2611. There is also variation in the nucleotide changes for these
sites.13,15,16,32 These two regions were the starting points of the search
for answers to the increase in telithromycin MIC or resistance. How-
ever, as no nucleotide changes or deletions were identified in either
region, the possibility of domain II or V providing the answers was
ruled out.
The L4 protein has been associated with large increases in telithro-
mycin MIC in S. pneumoniae. Insertion of six amino acids into a
highly conserved area of ribosomal L4 protein (63KPWRQKGTGRAR74)
has been associated with a 500-fold increase in the MIC of telithro-
mycin.32 Once again, there were no changes in the nucleotide
sequences and so the amino acid sequence of either J II 8 or M IV.
Changes within the L22 protein amino acid sequence have also been
reported as a cause of increased telithromycin MIC from 0.008 to
0.25 mg/L. This was due to three simultaneous amino acid mutations:
alanine-93 to glutamic acid-93, proline-91 to serine-91 and glycine-
83 to glutamic acid-83.16 The L22 protein binds primarily to the 23S
rRNA. Mutations in this protein could change the conformation of
23S rRNA and thus affect ketolide binding.19 In this study, the only
mutation that was found was in the L22 of J II 8, a highly telithro-
mycin-resistant strain. The mutation did not occur in mutants of the
same parent with MICs of 4 or 1 mg/L. The change at amino acid 94
from lysine to glutamine was between two previously documented
changes: glycine-95 to aspartic acid-95 and alanine-93 to glutamic
acid-93. The glycine-95 to aspartic acid-95 mutation was associated
with increases in erythromycin MIC from 0.03 to 1 mg/L and 0.015
to 0.25 mg/L. The two strains were selected with erythromycin and
roxithromycin, respectively.16 The alanine-93 to glutamic acid-93
mutation was in combination with two other changes as previously
mentioned. The change from ionic lysine to the neutral glutamine
near the 3′ end of the protein could result in a conformational change
of the protein and thus prevent telithromycin binding. The previously
documented changes at amino acids 93 and 95 may also cause a con-
formational change in the L22 protein and thus prevent erythromycin
binding.
No telithromycin resistance could be created from a macrolide-
susceptible strain. Therefore although telithromycin has high activity
against macrolide-resistant strains, if the strain is exposed to telithro-
mycin in vitro, the activity of telithromycin will fall such that the
strain becomes telithromycin-resistant within a few generations. The
highly telithromycin-resistant strain J II 8 had two mutations, one in
the erm(B) attenuator and the other in the L22 riboprotein. Whereas
this strain had two mutations, none of the other strains had any
mutations. Therefore, whereas in this strain these mutations are the
most probable cause of telithromycin resistance, this is not the case
with the other telithromycin-resistant strains.
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